On the development of novel targeted pain therapeutics
Xenon has entered into a strategic alliance with Genentech, a member of the Roche Group, to discover and develop compounds and companion diagnostics for the potential treatment of pain.
Xenon and Genentech will collaborate on the discovery of new therapeutic approaches for treating pain. Under the terms of the agreement, Genentech has an exclusive licence to compounds and a non-exclusive licence to diagnostics from Xenon for development and commercialisation of products.
Xenon will receive an undisclosed upfront payment, research funding and is eligible to receive research, development and commercialisation milestone payments of up to US$646m for multiple products and indications.
Xenon will also receive royalties on sales of products resulting from the collaboration.
Simon Pimstone, president and ceo of Xenon, said the collaboration would allow Xenon to ‘deepen and broaden our pipeline of novel medicines in development’.